Article
Oncology
Ruichong Ma, Margarida Rei, Isaac Woodhouse, Katherine Ferris, Sophie Kirschner, Anandhakumar Chandran, Uzi Gileadi, Ji-Li Chen, Mariana Pereira Pinho, Yoanna Ariosa-Morejon, Skirmantas Kriaucionis, Nicola Ternette, Hashem Koohy, Olaf Ansorge, Graham Ogg, Puneet Plaha, Vincenzo Cerundolo
Summary: This study demonstrates that the use of 5-aza-2-deoxycytidine (DAC) can increase the immunogenicity of glioblastoma and enhance T-cell activation and killing by increasing neoantigen presentation.
Review
Immunology
Erin E. Peterson, Kevin C. Barry
Summary: The intercellular cross-talk between NK cells and cDC1s plays a crucial role in immune responses to cancer, impacting the efficacy of certain immunotherapies and overall survival rates for patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Boyuan Huang, Xuesong Li, Yuntao Li, Jin Zhang, Zhitao Zong, Hongbo Zhang
Summary: Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor in the central nervous system. Immunotherapy has shown promising results in the treatment of GBM, but future developments will require an integrated approach with various treatment modalities and specific targeted therapies for the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Jennifer Moran, Eimear Mylod, Laura E. Kane, Caroline Marion, Emily Keenan, Marianna Mekhaeil, Joanne Lysaght, Kumlesh K. Dev, Jacintha O'Sullivan, Melissa J. Conroy
Summary: Glioblastoma multiforme (GBM), the most common primary brain malignancy in adults, has a low survival rate of about 14.6 months. The current standard-of-care for GBM includes surgery and chemoradiotherapy, but the response to treatment is limited due to factors such as tumor heterogeneity, treatment resistance, the blood-brain barrier, and immunosuppression. Olaparib, an FDA-approved drug for BRCA-mutated ovarian and breast cancer, has been found to enhance radio- and chemo-sensitivity in GBM and its ability to enhance natural killer (NK) cell-mediated responses is reported in other types of cancer. This study investigated the combination of Olaparib with NK cell therapies in GBM and found that Olaparib does not affect the susceptibility of GBM cells to NK cells or the function of NK cells. These findings provide new insights into the potential of combining Olaparib with NK cell therapies for GBM.
Review
Immunology
Olga Zimmermannova, Ines Caiado, Alexandra G. Ferreira, Carlos-Filipe Pereira
Summary: The development of cancer immunotherapy is based on advances in understanding the interaction between cancer cells and the immune system, with cell fate reprogramming providing new alternatives for personalized immunotherapy. Technologies such as induced pluripotent stem cells (iPSCs) enable the study and generation of clinically useful immune cells, offering potential for enhancing anti-tumor properties and addressing challenges in cellular immunotherapy. Advances in in vivo reprogramming and gene delivery mechanisms are opening exciting avenues for direct manipulation of immune or tumor cells in situ, providing new tools for overcoming obstacles in cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Shumin Luo, Jing Chen, Fang Xu, Huan Chen, Yiru Li, Weihua Li
Summary: This article summarizes a new approach in cancer immunotherapy, which is based on the exosomes derived from dendritic cells (DEXs). DEXs have the potential to improve therapeutic outcomes and overcome tumor cell-mediated immunosuppression. By capturing tumor antigens and promoting immune cell-dependent tumor rejection, DEXs play an important role in enhancing immune responses and overcoming immune escape by tumors.
Review
Immunology
Angeliki Datsi, Ruediger V. Sorg
Summary: Dendritic cell vaccination (DCV) is a promising immunotherapy for treating glioblastomas, with numerous trials showing potential but some controlled studies failing to detect a survival benefit. Further exploration is needed to fully understand the potential of this therapeutic approach.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Suprava Das, Banendu Sunder Dash, Thejas P. Premji, Jyh-Ping Chen
Summary: This review discusses the mechanisms, benefits, and limitations of various immunotherapeutic approaches for glioblastoma (GBM) treatment, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy. It emphasizes the importance of immunotherapy in overcoming the current treatment limitations and improving survival rates in GBM patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Xi Zhang, Tianhui He, Yuan Li, Ling Chen, Hongyu Liu, Yu Wu, Hongyan Guo
Summary: Ovarian cancer is characterized by uncertain presentation and poor outcomes, with surgery and chemotherapy being the current basis of treatment. However, there are limitations due to advanced stage at diagnosis and high recurrence rate. The use of anti-VEGF agents, PARP inhibitors, and immunotherapies are being explored to enhance treatment outcomes, but the population that can benefit from these treatments remains limited.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Pan Xie, Han Yan, Ying Gao, Xi Li, Dong-Bo Zhou, Zhao-Qian Liu
Summary: In this study, we established an m6A-related lncRNA risk model to predict the prognosis of glioblastoma multiforme (GBM) patients. The model showed good accuracy and effectiveness in predicting and assessing the survival of GBM patients, and it can function independently of other clinical characteristics. We also identified immune regulation pathways and anticancer drug sensitivity related to the risk model.
FRONTIERS IN ONCOLOGY
(2022)
Article
Engineering, Environmental
Meijuan He, Tingting Xiao, Yihui Wang, Hongwei Yu, Zilin Wang, Xiangyang Shi, Han Wang
Summary: In this study, we developed an immunostimulated nanoplatform for MRI-guided radiotherapy against GBM. The platform effectively enhances the immune response and shows promising therapeutic efficacy.
CHEMICAL ENGINEERING JOURNAL
(2023)
Review
Oncology
Mehrshad Ebrahim Pour, Samin Ghorbani Moghadam, Parian Shirkhani, Amirhossein Sahebkar, Fatemeh Mosaffa
Summary: Cell-based vaccines show promise as a potential therapeutic approach for GBM, with favorable safety profiles and modest improvements in patient survival. However, further advancements are needed to overcome limitations, such as the development of potent antigens and optimization of dosage regimens.
Article
Oncology
Jang Hyun Park, Heung Kyu Lee
Summary: Glioblastoma multiforme (GBM) is an aggressive tumor in the central nervous system, and its survival is affected by hypoxia, which promotes drug resistance and inhibits immune responses. Traditionally, hypoxia studies have focused on blood vessels and tumor cells, excluding the immune system. However, recent evidence suggests the important role of immunosurveillance in tumor hypoxia. This review discusses the clinical, pathological, and immunological perspectives of hypoxia in GBM.
Review
Chemistry, Multidisciplinary
Heng Dong, Qiang Li, Yu Zhang, Meng Ding, Zhaogang Teng, Yongbin Mou
Summary: Dendritic cell (DC)-based cancer immunotherapy has shown great potential in clinical application. However, traditional DC-mediated immunotherapy faces challenges such as insufficient antigen delivery, inadequate antigen presentation, and high levels of immunosuppression. To overcome these challenges, engineered biomaterials have been utilized to enhance the effects of DC-mediated immunotherapy. This review summarizes the key components that can enhance DC-mediated immunotherapeutic effects, discusses the parameters considered in the design of biomaterials, and reviews recent applications of engineered biomaterials in DC-mediated immunotherapy, including as delivery platforms and modulators of the tumor microenvironment. The review aims to inspire the clinical translation of future DC-mediated cancer immunotherapies.
Review
Clinical Neurology
Leili Shabani, Milad Abbasi, Masoomeh Amini, Ali Mohammad Amani, Ahmad Vaez
Summary: Nanotechnology has revolutionized the detection, screening, and treatment of malignant tumors and brain tumors. Nanostructures with great selectivity and special physicochemical properties serve as exceptional vehicles for delivering therapeutic agents.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)